Hueston Hennigan Secures Significant Victory for Samsung Bioepis at Third Circuit
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines by developing and manufacturing biosimilars. Janssen’s preliminary injunction motion sought to